✦ LIBER ✦

Correlation Between the Response to Cetuximab Alone or in Combination With Irinotecan and the Activated/Phosphorylated Epidermal Growth Factor Receptor in Metastatic Colorectal Cancer

✍ Scribed by Nicola Personeni; Alain Hendlisz; Julien Gallez; Maria Gomez Galdon; Denis Larsimont; Jean-Luc Van Laethem; Nathalie Nagy; Martine Barette; Marianne Paesmans; Fatima Cardoso; Harry Bleiberg

Book ID: 114473781
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 96 KB
Volume: 32
Category: Article
ISSN: 0093-7754
DOI: 10.1053/j.seminoncol.2005.04.029

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

1086 Cetuximab in a randomized phase II

1086 Cetuximab in a randomized phase II trial as a single agent or in combination with irinotecan in patients with epidermal growth factor receptor (EGFR)-expressing, irinotecan-refractory metastatic colorectal cancer (CRC)

✍ Van Cutsem, E.; Gascón Vilaplana, P.; Seitz, J.F.; Van Laethem, J.L.; Grossi, F. 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 159 KB

Mitogen-activated protein kinase phospha

Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients

✍ Montagut, C; Iglesias, M; Arumi, M; Bellosillo, B; Gallen, M; Martinez-Fernandez 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 603 KB

289 Phase II study of cetuximab combined

289 Phase II study of cetuximab combined with FOLFIRI (bi-weekly irinotecan plus infusional 5-FU and folinic acid (FA) in patients (pts) with metastatic, Epidermal growth factor receptor (EGFR)-expressing colorectal cancer (CRC)

✍ J.L. Raoul; J.L. van Laethem; E. Mitry; C. Brezault; F. Husseini; L. Cals; M. Pe 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 170 KB

702 PUBLICATION Cetuximab and irinotecan

702 PUBLICATION Cetuximab and irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (AIO) is active and safe in the first-line treatment of metastatic colorectal cancer (mCRC) expressing the epidermal growth factor receptor (EGFR)

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 134 KB

Cetuximab (C225, Erbitux) in combination

Cetuximab (C225, Erbitux) in combination with irinotecan, infusional 5-fluorouracil (5-FU) and folinic acid (FA) is safe and active in patients (pts) with metastatic colorectal cancer (CRC) expressing epidermal growth factor-receptor (EGFR). Results of a phase I study

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 306 KB

Epidermal Growth Factor Receptor (EGFR)

Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis

✍ Mario Scartozzi; Italo Bearzi; Alessandra Mandolesi; Chiara Pierantoni; Fotios L 📂 Article 📅 2009 🏛 BioMed Central 🌐 English ⚖ 279 KB